Enver Akalin, M.D.
Professor of Clinical Medicine, Department of Medicine (Nephrology)
Professor of Clinical Surgery, Department of Surgery
Enver Akalin, MD, earned his medical degree at Ege University School of Medicine in Izmir, Turkey. He completed a research fellowship in the Renal Division at Brigham and Woman’s Hospital, Harvard Medical School, followed by a clinical fellowship in the Renal Division at Boston University School of Medicine. Dr. Akalin completed his residency in Internal Medicine as well as a clinical transplant nephrology fellowship in the Renal Division at Emory University School of Medicine.
Dr Akalin, a UNOS-certified transplant nephrologist, brings to Montefiore more than a decade of expertise in kidney and kidney-pancreas transplantation. Prior to joining Einstein-Montefiore, Dr. Akalin served as the Medical Director of the Kidney and Pancreas Transplantation Program and the Director of the Transplant Nephrology Fellowship at Mount Sinai School of Medicine. Dr. Akalin is board certified by the American Board of Internal Medicine and the American Board of Nephrology.
Dr. Akalin is a member of several societies, has served on the American Society of Transplantation Clinical Trials Committee and Renal Accreditation Committee, the American Society of Nephrology Transplant Advisory Group and the Medical Board of New York Organ Donor Network. He currently serves on the Editorial Board of the Clinical Journal of The American Society of Nephrology. Dr. Akalin has been the principle investigator in several trials and has written numerous articles on complex issues in kidney transplantation.
Dr Akalin’s main research interest is investigating mechanisms of acute and chronic rejection using microarray technology and immune monitoring of kidney transplant recipients. Dr. Akalin is one of the first investigators that applied GeneChip (microarray) technology in human kidney transplantation. GeneChip is a powerful technology that detects thousands of genes simultaneously and might help to understand the mechanisms, diagnosis, and the treatment of complex disease, such as rejection of the kidney transplant. His other main research interest is kidney transplantation in highly sensitized cross-match positive or blood group incompatible kidney transplant recipients by using desensitization protocols with Intravenous Immunoglobulin, Rituximab, and Plasmapheresis. He investigates the mechanisms of desensitization treatment and its effect on donor-specific antibodies.
Dr Akalin is also involved in multicenter trials of new immunosuppressive medications as a principle investigator.
SELECTED RECENT PUBLICATIONS
- Akalin E, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, Lakkis FG. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001; 72 : 948-953
- Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW. Glomerular infiltration by CXCR3+ and ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003; 3:1116-1120
- Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Murphy B, Bromberg JS. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-735
- Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS. Intravenous immunglobulin (IVIG) and Thymoglobulin facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (FC) T and/or B cell cross-match positive patients. Transplantation 2003; 76:1444-1447
- Akalin E, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus positive kidney transplant recipients. Clinical Transplantation 2004; 18: 384-389
- Hotchkiss H, Chu T, Hancock WW, Schroppel B, Kretzler M, Schmid H, Liu Y, Dikman S, Akalin E. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 2006; 81: 342-349
- Akalin E, Dinavahi R, Dikman S, de Boccardo G, Friedlander R, Schroppel B, Sehgal V, Bromberg JS, Murphy B. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2(6): 1261-1267
- Akalin E, Dinavahi R, Friedlander R, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS. The addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3(4): 1160-1167
- Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with development of the composite outcomes of new cardiovascular disease and chronic allograft nephropathy. Transplantation 2008; 86: 652-658
- Rafiq M, de Boccardo G, Schroppel B, Bromberg J, Sehgal V, Dinavahi R, Murphy B, Akalin E. Differential outcomes in 3 types of acute-antibody mediated rejection. Clinical Transplantation 2009.
SELECTED REVIEW ARTICLES
- Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flowcytometry cross-match positive kidney transplant recipients. Human Immunology 2005; 66: 359-363
- Akalin E, Pascual M. Sensitization after kidney transplantation. Clin J Am Soc of Nephrol 2006; 1:3:433-440
- Akalin E, Watschinger B.Antibody-mediated rejection. Semin Nephrol 2007; 27 (4): 393-407
- Dinavahi R, Akalin E. Preemptive kidney transplantation in patients with diabetes mellitus. Endocrinology and Metabolism Clinics of North America 2007; 36(4): 1039-1049
- Akalin E. Posttransplant immunosuppression in highly sensitized patients. Cont Nephrol 2008; 4(9):484-485
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.